<?xml version="1.0" encoding="UTF-8"?>
<p id="Par47">BTH1677 has been well tolerated after single doses up to 6 mg/kg and after 7 daily doses up to 4 mg/kg in healthy subjects. Pharmacokinetic (PK) parameters were proportional with dose [
 <xref ref-type="bibr" rid="CR38">38</xref>]. Additionally, BTH1677 in combination with cetuximab, with or without irinotecan, was well tolerated with promising signs of efficacy in a phase Ib/II study in patients with recurrent or progressive metastatic colorectal cancer [
 <xref ref-type="bibr" rid="CR39">39</xref>]. We also recently reported that BTH1677 combined with cetuximab/carboplatin/paclitaxel significantly improved ORR compared with cetuximab/carboplatin/paclitaxel in first-line treatment of patients with advanced NSCLC [
 <xref ref-type="bibr" rid="CR40">40</xref>].
</p>
